Aeterna Zentaris Inc. ( (CSCI) ) has released its Q4 earnings. Here is a breakdown of the information Aeterna Zentaris Inc. presented to its investors.
COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse portfolio of cosmeceutical, nutraceutical, and pharmaceutical products, leveraging proprietary extraction technology for active ingredients from renewable plant resources.
In its latest earnings report, COSCIENS Biopharma Inc. highlighted a transformative year in 2024, marked by strategic repositioning as a pure-play natural-based product company. The company reported a significant increase in revenues and outlined ongoing efforts to streamline operations and prioritize its development pipeline.
For the full year 2024, COSCIENS reported revenues of $9.6 million, a 35.2% increase from the previous year, driven by sales of Avenanthramides and Beta Glucan. However, the company also faced a consolidated net loss of $15.3 million, attributed to increased research and development costs, selling, general and administrative expenses, and impairment charges. Key developments included successful Phase 1 results for Avenanthramides tablets and the launch of a Phase 2a clinical study, alongside plans for new product launches in the nutraceutical sector.
Despite the financial challenges, COSCIENS remains optimistic about its future, focusing on expanding its product offerings and leveraging its proprietary technology. The company aims to propel growth by advancing promising programs and exploring strategic options for its macimorelin asset.
Looking ahead, COSCIENS Biopharma Inc. is poised to continue its evolution as a natural-based life science company, with management expressing confidence in the company’s ability to achieve its strategic goals and drive future growth.